Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Neuroaffiming Autism and ADHD evaluation for adults and teens (Ages 12+) and holistic medication management & genesight testing for neurodivergent folx. I take a collaborative, non-pathologizing ...
In my 20 years of psychiatric practice in hospital, outpatient, community, and municipal settings, I've witnessed and participated in harms perpetrated by a pathologizing and disempowering health care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results